Journal article
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease
CC Teerlink, SN Thibodeau, SK McDonnell, DJ Schaid, A Rinckleb, C Maier, W Vogel, G Cancel-Tassin, C Egrot, O Cussenot, WD Foulkes, GG Giles, JL Hopper, G Severi, R Eeles, D Easton, Z Kote-Jarai, M Guy, KA Cooney, AM Ray Show all
Human Genetics | Published : 2014
Abstract
Previous GWAS studies have reported significant associations between various common SNPs and prostate cancer risk using cases unselected for family history. How these variants influence risk in familial prostate cancer is not well studied. Here, we analyzed 25 previously reported SNPs across 14 loci from prior prostate cancer GWAS. The International Consortium for Prostate Cancer Genetics (ICPCG) previously validated some of these using a family-based association method (FBAT). However, this approach suffered reduced power due to the conditional statistics implemented in FBAT. Here, we use a case-control design with an empirical analysis strategy to analyze the ICPCG resource for association..
View full abstractGrants
Awarded by National Human Genome Research Institute
Funding Acknowledgements
Partial support for L. A. C. A. and for all data sets with in the Utah Population Database (UPDB) was provided by Huntsman Cancer Institute, University of Utah and the Huntsman Cancer Institute's Cancer Center Support grant, P30 CA42014 from National Cancer Institute. Research was supported by the Utah Cancer Registry, which is funded by Contract No. HHSN261201000026C from the National Cancer Institute's SEER Program with additional support from the Utah State Department of Health and the University of Utah. A subcontract from Johns Hopkins University with funds provided by grant R01 CA89600 from the NIH National Cancer Institute (to L. A. Cannon Albright). The International Consortium for Prostate Cancer Genetics has provided access to genotyping for this study (U01CA089600). RE is supported by Cancer Research UK and Prostate Action (now Prostate Cancer UK) and National Institute of Health Research support to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. Robert Stephenson generously donated funds for the data analysis aspects of this project.